Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.

@article{Peir2013AssociationOM,
  title={Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.},
  author={Gloria Peir{\'o} and Francisca Mar{\'i}a Peir{\'o} and Fernando Ortiz-Mart{\'i}nez and Mar{\'i}a D Planelles and Laura S{\'a}nchez-Tejada and Cristina Alenda and Segundo Ceballos and Jos{\'e} S{\'a}nchez-Pay{\'a} and Juan B. M. Laforga},
  journal={Human pathology},
  year={2013},
  volume={44 2},
  pages={218-25}
}
The classification of endometrial carcinoma divided into types I and II has shown clinical usefulness. Molecular alterations of PTEN and Wnt/β-catenin have been identified in this neoplasia. However, the role of mammalian target of rapamycin according to subcellular localization in the pathogenesis of this neoplasia and its prognostic significance are not well defined. We studied the expression of phosphorylated mammalian target of rapamycin, PTEN, and β-catenin and their relationship with… CONTINUE READING